ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

SPRYNasdaqHealthcareBiotechnology
$9.07 -0.33 (-3.51%)

Company Overview

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Price Chart

Historical Trend (Absolute Values)
SPRY Price
05/1305/2105/29

Financial Metrics

Market Capitalization$850.04M
P/E Ratio
Earnings Per Share (EPS)-$2
Dividend Yield
Beta (Volatility)0.801
Price to Book (P/B)7.8801
52-Week Range$6.66 - $18.90

LAST SCRARED: May 31, 2026

Compare SPRY

Analyze valuation multiples and growth parameters side-by-side with other public equities.

Compare Stock Now
VersusHub

© 2026 VersusHub. All rights reserved.